Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 6 January 2016 from 10am to 5pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present: 1. Dr Amanda Adler (Chair) Present for all notes
2. Professor Ken Stein (Vice-Chair) Present for all notes
3. Dr Ray Armstrong Present for all notes
4. Dr Jeff Aronson Present for all notes
5. Professor John Cairns Present for all notes
6. Dr Neil losson Present for all notes
7. Dr Rebecca Kearney Present for all notes
8. Dr Sanjay Kinra Present for all notes
9. Dr Miriam McCarthy Present for all notes
10. Mr Christopher O'Regan Present for all notes
11. Dr Sanjeev Patel Present for all notes
12. Professor John Pounsford Present for all notes
13. Dr Danielle Preedy Present for all notes
14. Mr Alun Roebuck Present for all notes
15. Dr Nigel De-Kare Silver Present for all notes
16. David Thomson Present for all notes
17. Dr Nicky Welton Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Melinda Goodall Associate Director, National Institute for Health and Care Excellence Present for all notes

Jeremy Powell Project Manager, National Institute for Health and Care Excellence Present for all notes

Victoria Kelly Technical Analyst, National Institute for Health and Care Excellence Present for notes 1 to 20

Dr Rosie Lovett Technical Adviser, Present for notes 1 to 20
National Institute for Health and Clinical Excellence

Sophie Laurenson Technical Analyst, National Institute for Health and Care Excellence Present for notes 21 to 33

Raisa Sidhu Technical Adviser, National Institute for Health and Clinical Excellence Present for notes 21 to 33

Ben Kearns Research Associate, School of Health and Related Research, University of Sheffield Present for notes 1 to 18

Abdullah Pandor Research Fellow / Systematic Reviewer, School of Health and Related Research, University of Sheffield Present for notes 1 to 18

Professor Matt Stevenson Technical Director, School of Health and Related Research, University of Sheffield Present for notes 1 to 18

Dr Amit Bahl Consultant Clinical Oncologist, Bristol Cancer Institute, nominated by British Uro-Oncology Group (BUG) Present for notes 1 to 14

Dr Zafar Malik Consultant Clinical Oncologist, Bristol Cancer Institute, nominated by British Uro-Oncology Group (BUG) Present for notes 1 to 14

Hugh Gunn Trustee of TACKLE Nominated by TACKLE Present for notes 1 to 14

Allan Higgins Nominated by Prostate Cancer Support Organisation Present for notes 1 to 14

Nicola Huxley Associate Research Fellow, Peninsular Technology Assessment Group, University of Exeter Present for notes 21 to 31

Professor Martin Hoyle Health Economist, Peninsular Technology Assessment Group, University of Exeter Present for notes 21 to 31

Dr Saifee Mullamitha Consultant in Medical Oncology nominated by Roche Present for notes 21 to 29

Dr Vanessa Potter Consultant GI Medical Oncologist nominated by Present for notes 21 to 29
NCRI/RCP/RCR/ACP
Stuart Barber nominated by Beating Bowel Cancer Present for notes 21 to 29

Non-public observers:
Helen Barnett Medical editor, NICE Present for notes all notes
Jacoline Bouvy Scientific Adviser, Science Policy and Research Programme, NICE Present for notes all notes
Paulo Dias NICE Present for notes 1 to 29
Geoffrey Ellison Coordinator, Observational Data Unit Present for notes all notes
Chloe Kastoryano PIP Advisor, NICE Present for notes all notes
Else-Marije Krajenbrink Coordinator, NICE International Present for notes 21 to 29
Linda Laryea Assistant Research Manager – Technology Assessment Reviews (TARs), NIHR Present for notes all notes
Hannah Patrick Consultant Clinical Adviser, NICE Present for notes all notes
Penny Duckham Kaiser Foundation Present for notes 21 to 29

Notes
Welcome
1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen and cetuximab and panitumumab for previously untreated metastatic colorectal cancer.
2. The Chair welcomed Dr Rebecca Kearney back to the Committee.
3. The Chair informed the Committee that this would be Professor Ken Stein’s last meeting as Vice-Chair and she thanked him for his contribution.
4. Apologies were received from Anne Joshua, Professor Ruairidh Milne, Professor Stephen Palmer and Dr Marta Soares.

Any other Business
5. The Chair gave the Committee an update on developments in other ongoing Technology Appraisals.

Appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen [ID889]

Part 1 – Open session
6. The Chair welcomed the invited experts: Dr Amit Bahl, Dr Zafar Malik, Hugh Gunn, Allan Higgins, Ben Kearns, Abdullah Pandor and Professor Matt Stevenson to the meeting and they introduced themselves to the Committee.

7. The Chair welcomed company representatives from Sanofi to the meeting.

8. The Chair asked all Committee members to declare any relevant interests

8.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Neil Iosson, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, David Thomson and Dr Nicky Welton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.

9. The Chair asked all NICE Staff to declare any relevant interests.

9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.

10. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

10.1. Allan Higgins, Ben Kearns, Abdullah Pandor and Professor Matt Stevenson declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.

10.2. Dr Amit Bahl declared a personal financial interest as he has received honoraria for attending meetings and advisory boards for Sanofi, Astellas, Dendreon, Janssen, Amgen, Bayer and Roche.

10.2.1. It was agreed that this declaration would not prevent Dr Bahl from participating in this section of the meeting.

10.3. Dr Zafar Malik declared a personal financial interest as he given commercial and research consultancy advice to Sanofi, Astellas, Janssen and Amgen in the last twelve months.

10.3.1. It was agreed that this declaration would not prevent Dr Malik from participating in this section of the meeting.
10.4. Hugh Gunn declared a financial interest as Tackle receives grants from pharmaceutical companies.

10.4.1. It was agreed that this declaration would not prevent Mr Gunn from participating in this section of the meeting.

11. The Chair introduced the lead team, Professor John Cairns and Dr Danielle Preedy. They and the Chair gave presentations on the clinical effectiveness and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.

12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

13. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

14. The Chair then thanked the experts for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.

16. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

17. Discussion on confidential information continued.

18. The Chair then thanked the Evidence Review Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

19. The Committee continued to discuss the clinical and cost effectiveness of cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen.

19.1. The committee decision was based on consensus.

20. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer [ID794]

Part 1 – Open session

21. The Chair welcomed the invited experts: Dr Saifee Mullamitha, Dr Vanessa Potter, Stuart Barber, Nicola Huxley and Professor Martin Hoyle to the meeting and they introduced themselves to the Committee.
22. The Chair welcomed company representatives from Amgen and Merck Serono to the meeting.

23. The Chair asked all Committee members to declare any relevant interests

23.1. Dr Amanda Adler, Professor Ken Stein, Dr Ray Armstrong, Dr Jeff Aronson, Professor John Cairns, Dr Neil losson, Dr Rebecca Kearney, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, David Thomson and Dr Nicky Welton declared a non-personal specific financial interest as part of his team had produced the assessment report for this appraisal, although he had not been directly involved.

24. The Chair asked all NICE Staff to declare any relevant interests.

24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.

25. The Chair asked all other invited guests (assessment group and invited experts, not including observers) to declare their relevant interests.

25.1. Nicola Huxley and Professor Martin Hoyle declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.

25.2. Dr Saifee Mullamitha declared a personal financial interest as he has been invited to give talks and to chair meetings by Roche, Amgen and other pharmaceutical companies. He has also attended advisory boards for pharmaceutical companies and has been taken to conferences by pharmaceutical companies.

25.2.1. It was agreed that this declaration would not prevent Dr Mullamitha from participating in this section of the meeting

25.3. Dr Vanessa Potter declared a personal financial interest as MerckSerono provided funding for her to attend the ESMO 2014 meeting.

25.3.1. It was agreed that this declaration would not prevent Dr Potter from participating in this section of the meeting

25.4. Stuart Barber declared a financial interest as Beating Bowel Cancer receives funding from a number of pharmaceutical companies. He observed that this made up less than 10% of Beating Bowel Cancer’s total income.

25.4.1. It was agreed that this declaration would not prevent Mr Barber from participating in this section of the meeting
26. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

27. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

28. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

29. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

30. Discussion on confidential information continued. This information was supplied by the companies.

31. The Chair then thanked the Assessment Group representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

32. The Committee continued to discuss the clinical and cost effectiveness of cetuximab and panitumumab for previously untreated metastatic colorectal cancer.

32.1. The committee decision was based on consensus.

33. The Committee agreed to defer a decision on the content of the guidance section of the Final Appraisal Determination (FAD) until further analyses had been undertaken.

**Date, time and venue of the next meeting**

34. Wednesday 3 February 2016 at Prospero House, 241 Borough High Street, London, SE1 1GA